FDA partial clinical hold on Curis' TakeAim Lymphoma study; no new enrollment

CURIS INC

FDA placed partial clinical hold on Phase 1/2 TakeAim Lymphoma study of emavusertib in B-cell malignancies.
No new patients can be enrolled; current participants benefiting may continue at 300mg BID or lower after reconsent.
Hold follows prior partial hold on TakeAim Leukemia study announced April 4, 2022; company had already paused enrollment voluntarily.
FDA requests additional safety, efficacy, and rhabdomyolysis data; company to provide updated guidance after holds resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.